AbbVie Inc. (ABBV) Factsheet

AbbVie Inc. (ABBV) Stock Analysis

Analysis from 10-Q filed 2026-11-03. Data as of Q3 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 20.4%. FCF margin 28.6%. Source: 10-Q filed 2026-11-03.

Metric	Value	Context
ROIC	20.4%	Above industry average
FCF Margin	28.6%	Strong cash generation

ROIC 20.4% — Top 25% of sector peers. FCF margin 28.6% — Top 25%.

Explore AbbVie Inc.: Earnings History | Overview

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ABBV: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: AbbVie Inc. earns 20.4% ROIC, Top 25% in Healthcare

ROIC TTM 20.4%, sector median -8.0%, Top 25%. DuPont: NOPAT margin 26.0% × asset turnover 0.5x. Gross margin 73.7%. Operating margin 32.2%. Source: 10-Q filed 2026-11-03.

Metric	ABBV	Rating	Context
Return on Invested Capital (ROIC)	20.4%	Excellent	Above sector median of -8.0%
Gross Margin	73.7%	Excellent	Strong pricing power
Operating Margin	32.2%	Excellent	Efficient operations

---

Cash Flow: AbbVie Inc. generates $18.9B FCF at 28.6% margin, positive NaN/8 quarters

FCF TTM $18.9B. FCF margin 28.6%, Top 25%. OCF/Net income 1.9x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-11-03.

Metric	ABBV	Rating	Context
Free Cash Flow Margin	28.6%	Excellent	Excellent cash conversion
Free Cash Flow (TTM)	$18.9B	Good	Positive cash generation
OCF/Net Income	1.9x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet Analysis for AbbVie Inc.

Total debt $80.9B, cash & investments $10.8B. Interest coverage 7.1x. Source: 10-Q filed 2026-11-03.

Metric	ABBV	Rating	Context
Net Cash Position	$-70.1B	Warning	Net debt position
Interest Coverage	7.1x	Good	Comfortable debt service

---

Valuation: AbbVie Inc. trades at 50.6x earnings

P/E 50.6x. EV/Sales 8.9x. FCF yield 3.6%. Dividend yield 2.3%. Source: 10-Q filed 2026-11-03.

Metric	ABBV	Rating	Context
P/E Ratio	50.6x	Warning	Premium valuation
EV/Sales	8.9x	Adequate	Growth premium priced in
FCF Yield	3.6%	Adequate	Lower cash yield
Dividend Yield	2.3%	Adequate	Growth focus over income

---

Capital Allocation: AbbVie Inc. returns 2.6% shareholder yield

Total shareholder yield 2.6% (div 2.3% + buyback 0.3%). Share count +0.0% YoY. Capital returned $13.6B TTM. Source: 10-Q filed 2026-11-03.

Metric	ABBV	Rating	Context
Total Shareholder Yield	2.6%	Adequate	Dividend + buyback yield combined
Buyback Yield	0.3%	Adequate	Minimal buyback activity
Share Count Change (YoY)	0.0%	Adequate	Net dilution from issuance/SBC
Total Capital Returned (TTM)	$13.6B	Good	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	20.4%	Top 25%	-
Free Cash Flow Margin	28.6%	Top 25%	8.8x above
Gross Margin	73.7%	Top 50%	1.2x above
Operating Margin	32.2%	Top 25%	-
P/E Ratio	50.6x	N/A	-

---

Financial Scorecard

Metric	ABBV	Rating	Sector Context
Return on Invested Capital (ROIC)	20.4%	Excellent	Top 25% of sector (median: -8.0%)
Free Cash Flow Margin	28.6%	Excellent	Top 25% of sector (median: 3.3%)
Gross Margin	73.7%	Excellent	Top 50% of sector (median: 63.9%)
P/E Ratio (Price-to-Earnings)	50.6x	Warning	High expectations priced in
Free Cash Flow Yield	3.6%	Adequate	Moderate yield

---

Frequently Asked Questions

Q: What is AbbVie Inc.'s Return on Invested Capital (ROIC)?

AbbVie Inc. (ABBV) has a trailing twelve-month Return on Invested Capital (ROIC) of 20.4%. The 8-quarter median ROIC is 13.2% with a improving trend. Sector median -8.0%. Source: 10-Q filed 2026-11-03.

Q: What is AbbVie Inc.'s Free Cash Flow Margin?

AbbVie Inc. (ABBV) has a free cash flow margin of 28.6%, generating $18.9 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-11-03.

Q: What is AbbVie Inc.'s P/E ratio and how does it compare to peers?

AbbVie Inc. (ABBV) trades at a P/E ratio of 50.6x, which is above the sector median of N/A. EV/Sales 8.9x. FCF yield 3.6%. Source: 10-Q filed 2026-11-03.

Q: Does AbbVie Inc. pay a dividend?

AbbVie Inc. (ABBV) currently pays a dividend yield of 2.3%. Total shareholder yield (dividend + buybacks) 2.6%. Source: 10-Q filed 2026-11-03.

Q: What is AbbVie Inc.'s revenue and earnings growth?

AbbVie Inc. (ABBV) grew revenue by 10.7% year-over-year. EPS +340.2% YoY. Source: 10-Q filed 2026-11-03.

Q: Is AbbVie Inc. buying back stock?

AbbVie Inc. (ABBV) repurchased $1.5 billion of stock over the trailing twelve months. This represents a buyback yield of 0.3%. Share count +0.0% YoY. Source: 10-Q filed 2026-11-03.

Q: How does AbbVie Inc. compare to competitors in Healthcare?

Compared to other companies in Healthcare, AbbVie Inc. (ABBV) shows: ROIC 20.4%, sector median -8.0% (Top 25%). FCF margin 28.6%, sector median 3.3% (Top 25%). Gross margin 73.7%, 9.9pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with AbbVie Inc.?

No quantitative warning flags fired for AbbVie Inc. (ABBV) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-11-03.

---

Data Source: Data sourced from 10-Q filed 2026-11-03. TTM metrics as of Q3 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.